Skip to main content
. 2021 Nov 30;11:23132. doi: 10.1038/s41598-021-02437-2

Table 3.

Characteristics at ICU admission and process of care during the ICU stay.

Characteristics
Median [IQR] or n (%)
MD All
N = 488
AO
N = 81
No AO
N = 407
p value
ICU admission diagnoses 0
ACS 232 (47.5) 40 (49.4) 192 (47.2) 0.7
Severe VOE 104 (21.3) 4 (4.9) 100 (24.6)  < 0.0001
Sepsis a 42 (8.6) 17 (21.3) 25 (6.1)  < 0.0001
Pulmonary embolism 18 (3.7) 5 (6.3) 13 (3.2) 0.19
Drug /morphine overdose 12 (2.5) 3 (3.7) 9 (2.2) 0.42
Other VOEb 83 (17) 13 (16) 70 (17.3) 0.8
Other diagnosesc 48 (9.8) 17 (21) 31 (7.6) 0.0002
Acute organ failure 3
Acute respiratory distress 116 (23.9) 31 (38.8) 85 (21) 0.0008
Shock 14 (2.9) 6 (7.5) 8 (2) 0.02
Coma 15 (3.1) 8 (10) 7 (1.7)  < 0.001
Acute kidney injury 3 (0.6) 1 (1.2) 2 (0.5) 0.42
Multi-organ failure 7 (1.4) 7 (8.8) 0 (0)  < 0.00001
Vital parameters at ICU admission
MBP (mmHg) 29 90 [80–100] 87 [76–100] 90 [80–99] 0.3
Heart rate (beats/min) 31 100 [84–115] 110 [96–125] 97 [82–112]  < 0.0001
Respiratory rate (breaths/min) 117 24 [18–30] 28 [23–32] 23 [17–28]  < 0.0001
Oxygen saturation (%) 41 98 [96–100] 98 [96–100] 99 [96–100] 0.13
Visual pain scale 226 7 [4–8] 7 [3–8] 7 [4–8] 0.48
GCS score 42 15 [15–15] 15 [14, 15] 15 [15–15]  < 0.001
Temperature (°C) 73 37.4[36.9– 38.2] 37.7 [37–38.6] 37.3[36.9– 38.1] 0.33
Laboratory tests at ICU admission
Haemoglobin (g/dL) 10 8 [6.7–9.1] 8.1 [6.2–9.4] 8 [6.7–9.1] 0.68
Leucocytes (G/L) 17 15.1 [11–20] 17 [12.7–24] 15 [11.2–20]  < 0.0001
Platelets (G/L) 12 264 [170–360] 192 [123–303] 276 [183–374] 0.0002
Creatinine (µmol/L) 10 54 [41–72] 75 [53–173] 52 [40–66]  < 0.0001
PT (%) 45 68 [57–78] 61 [36–71] 69 [60–78]  < 0.0001
Arterial lactate (mmol/L) 44 0.9 [0.6–1.4] 1.8 [1–3.5] 0.8 [0.6–1.2]  < 0.0001
Haemoglobin S (%) 47 77 [59–85] 68.1 [41.5–75] 78.9 [60.9 -85.3]  < 0.0001
Haemolytic parameters: 118 1.3 [1–2.3] 2.1 [1.2–5] 1.2 [1, 2] 0.99
 ASAT (xN) 125 1 [1–1.7] 1 [1, 2] 1 [1–1.6] 0.42
 ALAT (xN) 197 41 [24–77] 58 [27–103] 39 [23–71] 0.16
 Total bilirubin (µmol/L) 221 14 [8–28] 22.5 [11–53] 13 [823] 0.009
 Direct bilirubin (µmol/L) 336 2.4 [1.7–4.6] 3.6 [2–10.3] 2.3 [1.6–3.7] 0.002
 LDH (xN)
Treatment in the ICU
Opioids 0 391 (80.1) 60 (74.1) 331 (81.3) 0.14
Ketamine 0 115 (23.6) 9 (11.1) 106 (26) 0.005
NSAIDs 0 26 (5.3) 1 (1.2) 25 (6.1) 0.11
Blood transfusion 0 127 (26) 33 (40.7) 94 (23.1) 0.001
 Number of RBC packs 0 0 [0–2] 2 [0–2] 0 [0–2] 0.518
Exchange transfusion 0 114 (23.3) 21 (25.9) 93 (22.8) 0.23
 Number of RBC packs 0 4 [2–5] 0 [0–4] 2 [2–4] 0.0006
Bloodletting 12 (2.5) 0 (0) 12 (3) 0.003
Steroids 0 15 (3.1) 8 (9.9) 7 (1.7)
Antibiotics 361 (73.8) 71 (87.7) 289 (71)
Life-supporting treatments 0
NIV 29 (5.9) 29 (35.8) 0 (0)
MV 46 (9.4) 46 (56.8) 0 (0)
 Duration (days) 5 [2–10] 5 [2–10] 0 (0)
Vasoactive drugs 32 (6.6) 32 (39.5) 0 (0)
RRT 18 (3.7) 18 (22.2) 0 (0)
Veno-venous ECMO 5 (1) 5 (6.2) 0 (0)
Arterio-venous ECMO 3 (0.6) 29 (35.8)
SAPS II 88 16 [10–25] 34 [24–41] 15 [10–22]  < 0.0001

Significant values are in [bold].

The p values were obtained by univariate logistic regression and reflect associations with the occurrence of adverse outcomes.

IQR interquartile range, MD missing data, AO adverse outcome defined as death or use of life-sustaining treatments, SCD sickle cell disease, MBP mean arterial blood pressure, GCS Glasgow Coma Scale, ASAT aspartate transaminase, ALAT alanine transaminase, LDH lactate dehydrogenase, PT prothrombin time, ICU intensive care unit, NSAIDs nonsteroidal anti-inflammatory drugs, RBC red blood cells, LOS length of stay, ACS acute chest syndrome, VO vaso-occlusive, VOE vaso-occlusive event, NIV non-invasive ventilation, MV endotracheal mechanical ventilation, RRT renal replacement therapy, ECMO extracorporeal membrane oxygenation, SAPS II Simplified Acute Physiology Score II.

aSepsis was suspected when mentioned in medical records and confirmed when the patient had an infection accompanied with a life-threatening organ dysfunction.

bIncluding delayed haemolytic transfusion reaction, stroke, acute anaemia, priapism, splenic sequestration, VOE without severe pain, and VOE after surgery or childbirth.

cIncluding cardiac arrest, pulmonary oedema, acute coronary syndrome, exacerbation of chronic respiratory failure, seizure and status epilepticus, acute kidney failure, metabolic disorders, pancreatitis, hepatitis, gastro-intestinal bleeding, gastro-intestinal occlusion, mesenteric ischaemia, haematologic disorders, anaphylaxis, and peri-partum complications.